Instrutor in Pediatrics| BCH | Harvard | Exploring how genetic and epigenetic mechanisms regulate #ACC immune evasion using functional genomics.
Brookline, MA
Joined July 2010
- Tweets979
- Following684
- Followers297
- Likes61.1K
Pinned Tweet
Excited to share our paper on a new model of #adrenocorticalcarcinoma published in @oncogenejournal!Congrats to the team for achieving this! #Breaultlab @MdBreault nature.com/articles/s41388-0… – at Brookline, MA
Kleiton Borges retweeted
Por que uma Santa desperta tanto ódio em quem quer mandar no país?
🔦 Revelando: A Guerra à Santa, com Juliette.
Assista agora: youtu.be/j4Y2XoS_KIY
Kleiton Borges retweeted
Thank you to everyone who has reached out in support of Lito Sousa. We are in contact with his team to help evaluate his options. (1/2)
Kleiton Borges retweeted
Read new directive from @theNCI regarding justifying animal model use in grant applications
cancer.gov/grants-training/n…
"when grant proposals contain animal experiments, the proposal should also contain a plan for validation of the findings of this animal experiment in a human model"
Kleiton Borges retweeted
Hello friends!!! Helps us to celebrate pancreatic cancer survivors, patients and their families!!! Help us to raise funds for this cause!!! Any donation is appreciated!!! Let's take steps together at PurpleStride! secure.pancan.org/site/TR/Pu…
Kleiton Borges retweeted
ICYMI: In order to address the backlog of applications scheduled for peer review, emergency modifications to #NIH review processes and policies will be made. Read more: go.nih.gov/d3IPLBP
Kleiton Borges retweeted
Thrilled to share that I’ve been awarded the K99/R00! A bright milestone amid challenges, made possible thanks to my amazing mentors @Salic_Lab @MdBreault, collaborators, and @NIGMS. Excited for the road ahead exploring the mechanisms of carrier-mediated WNT release and activity!
Kleiton Borges retweeted
The last few days have been filled with good news. I’m super happy to announce that my PhD paper is (finally) out! 🥳 This was a long time coming due to all the circumstances with the pandemic, moving labs, stepping away from the bench… but it’s out! nature.com/articles/s41598-0…
Kleiton Borges retweeted
Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis biorxiv.org/content/10.1101/… #biorxiv_cancer
Kleiton Borges retweeted
From the September issue: Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets doi.org/10.1158/2159-8290.CD…
By @Vindhya_Vijay, Negin Karisani,@getz_lab, Nabeel Bardeesy, and colleagues @MGHCancerCenter @broadinstitute
Kleiton Borges retweeted
Excited to share our new story @NatImmunol! We hope this becomes a valuable resource and sparks new approaches for patients with low-grade gliomas. Great team effort and fun - Canada and Germany @mcgillu @DKFZ #BrainTumorAwareness
nature.com/articles/s41590-0…
Kleiton Borges retweeted
"Now, 8 years after beginning immunotherapy, John’s scans show no signs of disease. He has been off all treatment for almost 2 years," @TuftsMedicine describes. Discover CRI ImmunoAdvocate John's story of survival: bit.ly/46kH9IT #Immunotherapy #CancerSurvivor
Kleiton Borges retweeted
Following a year and a half long battle with melanoma, David learned that the cancer had spread to his liver, lungs and spine. "There is no doubt that immunotherapy saved my life," he emphasizes. Discover: bit.ly/4ojgrXJ #Immunotherapy #CancerResearch #CancerSurvivor
Kleiton Borges retweeted
1/
Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet?
If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from?
A short 🧵 on the origins, function, and significance of Ki-67. #IHC #pathx #molpath
Kleiton Borges retweeted
Very honored to have given this Rising Star interview, where I could talk a bit about myself, my research, my passion for microscopy, and my dream to find a cure for #LongCovid one day 🥹
Link for the full interview: short-link.me/123uR
Press release:
eurekalert.org/news-releases…
Kleiton Borges retweeted
Our new paper is out in @ScienceMagazine! By exploring the rich genetic diversity of Brazil, we show how fine-scale genomic analyses reveal that this diversity, rooted in Indigenous ancestry and centuries of complex demographic history, plays a key role in population health.
Kleiton Borges retweeted
Thrilled to share our work mapping dependencies in molecularly distinct, lineage-based BTC subtypes.
Extremely thankful to @targetcancer for believing in this work from the very beginning and to @curecc for multiple research fellowships that helped make this possible.
Now online in @CD_AACR: Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets - by @Vindhya_Vijay, Negin Karisani,@getz_lab, Nabeel Bardeesy, and colleagues doi.org/10.1158/2159-8290.CD… @MGHCancerCenter @broadinstitute
Kleiton Borges retweeted
🚨 New from our lab!
Huge congrats to my amazing colleague and friend @Vindhya_Vijay —so proud of this work!
A powerful resource for the cholangio field combining multi-omics and CRISPR screens across 63 biliary tract cancer (BTC) cell lines. Check it out!
@targetcancer @curecc
Now online in @CD_AACR: Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets - by @Vindhya_Vijay, Negin Karisani,@getz_lab, Nabeel Bardeesy, and colleagues doi.org/10.1158/2159-8290.CD… @MGHCancerCenter @broadinstitute
Kleiton Borges retweeted
Adrenal tumors can sometimes produce an excess of hormones called aldosterone, cortisol, androgens, or adrenaline. Too much of these hormones may cause serious health problems or symptoms. #AADAM2025 @NADF_adrenal @TheEndoSociety @TheAACE
Kleiton Borges retweeted
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases.
I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known.
People can contact me directly at my first name (as written in my profile) at octant.bio.
